Range |
17-85 years |
17-85 years |
Median |
55 years |
55 years |
Sex |
Sex |
Sex |
Female |
39 |
52.7% |
Male |
35 |
47.3% |
Insect |
Insect |
Insect |
Bee |
16 |
21.6% |
Wasp |
58 |
78.4% |
Treatment |
Treatment |
Treatment |
Beta blockers |
3 |
4.1% |
ACE- inhibitors |
0 |
0% |
Grade of SR |
Grade of SR |
Grade of
SR |
I |
0 |
0% |
II |
20 |
27% |
III |
46 |
62.1% |
IV |
8 |
10.8% |
Reactions during up-dosing (n=74) |
Reactions during
up-dosing (n=74) |
Reactions during up-dosing
(n=74) |
No side effects |
67 |
90.5% |
Large Local reactions |
4 |
5.4% |
Subjective systemic symptoms |
3 |
4.1% |
Objective systemic symptoms |
0 |
0% |
Total incidence of adverse reactions |
7 |
9.5% |
Reactions during maintenance (n=74) |
Reactions during
maintenance (n=74) |
Reactions during maintenance
(n=74) |
No side effects |
67 |
90.5% |
Large Local reactions |
3 |
4.1% |
Subjective systemic symptoms |
3 |
4.1% |
Objective systemic symptoms |
1 |
1.4% |
Total incidence of adverse reactions |
7 |
9.5% |
Field stings |
Field stings |
Field stings |
During up-dosing |
During up-dosing |
During
up-dosing |
Localised reaction |
5 |
6.8% |
Systemic reaction |
0 |
0% |
During maintenance |
During maintenance |
During maintenance |
Localised reaction |
15 |
20.3% |
Systemic reaction |
0 |
0% |